Home
>
Analytes
>
Heart Parameters
> NT-proBNP
|
NT-proBNP
Literature
|
 |
 |
Literature
Bay M, Kirk V, Parner J, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003; 89:150-154
Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004; 6:359-363.
Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004; 6:327-333.
Hess G. NT-proBNP in normal healthy blood donors and individuals with heart failure. Submitted.
Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47:287.
Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and non ST-segment elevation. J Am Coll Cardiol 2002; 40:437-445.
Luchner A, Hengstenberg C, Lowel H, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002; 39:99-104.
Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39:571-588.
Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non cardiac dyspnea. Eur J Heart Fail 2004; 6:63-70.
Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Stellenwert der natriuretischen Peptide NT-proBNP und BNP für die Beurteilung der linksventrikulären Größe und Funktion. Dtsch Med Wochenschr 2002; 127:2605-2609.
Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force report. Eur Heart J 2001; 22:1527-1560.
Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohumoral predictors of left ventricular dysfunction and prognosis after myocardial infarction. Circulation 1998; 97:1921-1299.
Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro brain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2001; 37:1781-1787.
Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 2004; 6:351-354.
Roche Diagnostics. Package insert Elecsys proBNP, EU version.
Roche Diagnostics. Package insert Elecsys proBNP, US version.
Talwar S, Downie PF, Ng LL, Squire IB. Towards a blood test for heart failure: the potential use of circulating natriuretic peptides. Br J Clin Pharmacol 2000; 50:15-20.
Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy and left ventricular systolic dysfunction on plasma N-terminal pro BNP. Heart 2000; 83:278-282.
Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 1999; 20:1736-1744.
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.
|
 |
|
|
|
|
| |
|
|
This website contains information on products which is targeted to a wide
range of audiences and could contain product details or information
otherwise not accessible or valid in your country. Please be aware that we
do not take any responsibility for accessing such information which may not
comply with any valid legal process, regulation, registration or usage in
the country of your origin.
|
| |
